The allogeneic CAR-T product candidate is being developed in partnership with Roche for relapsed/refractory multiple myeloma (RRMM). P-BCMA-ALLO1 targets the B-cell maturation antigen (BCMA) and is enriched with
The submission is scheduled for mid-2024, following constructive pre-submission meetings with EU regulatory authorities. The company also plans to engage with the US Food and Drug Administration (FDA)
A dual-acting IL-23 inhibitor, TREMFYA acts on both IL-23 and CD64 to potentially provide relief for patients. The sBLA is based on the data from the Phase III
This label expansion follows a supplemental New Drug Application (sNDA) submitted by the company. As per the latest approval, the treatment is indicated for reducing risks of major
Following the analysis of cambritaxestat’s chemical and biological properties, including a promising non-clinical safety and efficacy profile, the US regulator granted the ODD status. This designation provides benefits
The fundraising was spearheaded by Enavate Sciences, with Viking Global Investors and Perceptive Advisors joining as new investors. The financing round also saw contributions from all current stakeholders,
This recommendation, part of NICE’s final draft guidance, could potentially benefit nearly 540 adults. A monoclonal antibody, Dostarlimab works by aiding the immune system in combating cancer. Administered
This marks a significant advancement in ophthalmic care, introducing the first FDA-approved ophthalmic formulation of clobetasol propionate, a corticosteroid and the first new steroid in the ophthalmic market
This marks a significant step in the potential approval of the medication for use in the European Union. One application pertains to the treatment of adults with locally
The financing round was led jointly by Alaska Permanent Fund Corporation, Cure Ventures, and The Column Group, with additional contributions from Euclidean Capital and Saisei Ventures. Previously operating
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.